Aspire Private Capital’s Scinai Immunotherapeutics SCNI Stock Holding History

Aspire Private Capital’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-32	Closed	-$110	–	539
2024 Q3	$110	Hold	32	–	–	﹤0.01%	654
2024 Q2	$89	Buy	32 +16	+100%	+$66	﹤0.01%	671
2024 Q1	$83	Hold	16	–	–	﹤0.01%	703
2023 Q4	$95	Hold	16	–	–	﹤0.01%	685
2023 Q3	$139	Hold	16	–	–	﹤0.01%	680
2023 Q2	$226	Hold	16	–	–	﹤0.01%	643
2023 Q1	$346	Hold	16	–	–	﹤0.01%	611
2022 Q4	$474	Hold	16	–	–	﹤0.01%	600
2022 Q3	$1K	Hold	16	–	–	﹤0.01%	586
2022 Q2	$2K	Buy	16 +8	+100%	+$1.1K	﹤0.01%	507
2022 Q1	$1K	Buy	+8	New	+$1.16K	﹤0.01%	562

Other funds holding SCNI

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Aspire Private Capital's SCNI Position: Q4 2024 in Review

Aspire Private Capital sold out of Scinai Immunotherapeutics (SCNI) in Q4 2024, closing a stake of 32 shares — an estimated $110 sold.

Aspire Private Capital first reported a position in SCNI in Q1 2022 and held it in 11 quarters. The position peaked at $2K in Q2 2022. 4 funds tracked by Wall St. Rank hold SCNI as of Q4 2024.

Aspire Private Capital reported no remaining Scinai Immunotherapeutics position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 32 Scinai Immunotherapeutics shares in Q4 2024, an estimated $110.
Aspire Private Capital first reported a position in Scinai Immunotherapeutics in Q1 2022 and held it in 11 quarters.
Aspire Private Capital's Scinai Immunotherapeutics position peaked at $2K in Q2 2022.
4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.